 |
Recombinant humanized immunoglobulin gamma 1 monoclonal antibody (mAb) directed against the CemX segment of human membrane-bound immunoglobulin E (mIgE) |
|---|---|
| Trade Name | |
| Orphan Indication | Hyper-IgE Syndrome |
| USA Market Approval | USA |
| USA Designation Date | 2017-09-28 00:00:00 |
| Sponsor | Fountain Biopharma, Inc.;19F-1, No. 3, 3 Yuan Qu Street;Nangang District |
Related Access Program